Effects of triple therapy on disease burden in patients of GOLD groups C and D : results from the observational COPD cohort COSYCONET
© 2024. The Author(s)..
BACKGROUND: Randomized controlled trials described beneficial effects of inhaled triple therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) and high risk of exacerbations. We studied whether such effects were also detectable under continuous treatment in a retrospective observational setting.
METHODS: Data from baseline and 18-month follow-up of the COPD cohort COSYCONET were used, including patients categorized as GOLD groups C/D at both visits (n = 258). Therapy groups were defined as triple therapy at both visits (triple always, TA) versus its complement (triple not always, TNA). Comparisons were performed via multiple regression analysis, propensity score matching and inverse probability weighting to adjust for differences between groups. For this purpose, variables were divided into predictors of therapy and outcomes.
RESULTS: In total, 258 patients were eligible (TA: n = 162, TNA: n = 96). Without adjustments, TA patients showed significant (p < 0.05) impairments regarding lung function, quality of life and symptom burden. After adjustments, most differences in outcomes were no more significant. Total direct health care costs were reduced but still elevated, with inpatient costs much reduced, while costs of total and respiratory medication only slightly changed.
CONCLUSION: Without statistical adjustment, patients with triple therapy showed multiple impairments as well as elevated treatment costs. After adjusting for differences between treatment groups, differences were reduced. These findings are compatible with beneficial effects of triple therapy under continuous, long-term treatment, but also demonstrate the limitations encountered in the comparison of controlled intervention studies with observational studies in patients with severe COPD using different types of devices and compounds.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
BMC pulmonary medicine - 24(2024), 1 vom: 01. März, Seite 103 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zader, Jennifer A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 13.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12890-024-02902-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369144228 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369144228 | ||
| 003 | DE-627 | ||
| 005 | 20240313234546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12890-024-02902-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM369144228 | ||
| 035 | |a (NLM)38424530 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zader, Jennifer A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of triple therapy on disease burden in patients of GOLD groups C and D |b results from the observational COPD cohort COSYCONET |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a BACKGROUND: Randomized controlled trials described beneficial effects of inhaled triple therapy (LABA/LAMA/ICS) in patients with chronic obstructive pulmonary disease (COPD) and high risk of exacerbations. We studied whether such effects were also detectable under continuous treatment in a retrospective observational setting | ||
| 520 | |a METHODS: Data from baseline and 18-month follow-up of the COPD cohort COSYCONET were used, including patients categorized as GOLD groups C/D at both visits (n = 258). Therapy groups were defined as triple therapy at both visits (triple always, TA) versus its complement (triple not always, TNA). Comparisons were performed via multiple regression analysis, propensity score matching and inverse probability weighting to adjust for differences between groups. For this purpose, variables were divided into predictors of therapy and outcomes | ||
| 520 | |a RESULTS: In total, 258 patients were eligible (TA: n = 162, TNA: n = 96). Without adjustments, TA patients showed significant (p < 0.05) impairments regarding lung function, quality of life and symptom burden. After adjustments, most differences in outcomes were no more significant. Total direct health care costs were reduced but still elevated, with inpatient costs much reduced, while costs of total and respiratory medication only slightly changed | ||
| 520 | |a CONCLUSION: Without statistical adjustment, patients with triple therapy showed multiple impairments as well as elevated treatment costs. After adjusting for differences between treatment groups, differences were reduced. These findings are compatible with beneficial effects of triple therapy under continuous, long-term treatment, but also demonstrate the limitations encountered in the comparison of controlled intervention studies with observational studies in patients with severe COPD using different types of devices and compounds | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a COPD | |
| 650 | 4 | |a Health care costs | |
| 650 | 4 | |a Lung function | |
| 650 | 4 | |a Symptoms | |
| 650 | 4 | |a Triple therapy | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Adrenergic beta-2 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Muscarinic Antagonists |2 NLM | |
| 700 | 1 | |a Jörres, Rudolf A |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Imke |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Bals, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Watz, Henrik |e verfasserin |4 aut | |
| 700 | 1 | |a Mertsch, Pontus |e verfasserin |4 aut | |
| 700 | 1 | |a Rabe, Klaus F |e verfasserin |4 aut | |
| 700 | 1 | |a Herth, Felix |e verfasserin |4 aut | |
| 700 | 1 | |a Trudzinski, Franziska C |e verfasserin |4 aut | |
| 700 | 1 | |a Welte, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Kauczor, Hans-Ulrich |e verfasserin |4 aut | |
| 700 | 1 | |a Behr, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Walter, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Vogelmeier, Claus F |e verfasserin |4 aut | |
| 700 | 1 | |a Kahnert, Kathrin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC pulmonary medicine |d 2001 |g 24(2024), 1 vom: 01. März, Seite 103 |w (DE-627)NLM114960313 |x 1471-2466 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2024 |g number:1 |g day:01 |g month:03 |g pages:103 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12890-024-02902-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2024 |e 1 |b 01 |c 03 |h 103 | ||